RNA, U6 small nuclear 237, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-237P profile across patient tissues and cancer cell-line models. RNU6-237P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNU6-237P is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, RNU6-237P RNA expression shows 11,316 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, BRCA, and UVM as cancer lineages where RNU6-237P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-237P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-237P survival associations across molecular data types. RNU6-237P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-237P RNA expression–survival associations across cancer types. High RNU6-237P expression shows unfavorable associations in MESO, UVM, LUSC and LGG, but favorable associations in UCS and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify MESO as the clearest survival context for RNU6-237P RNA expression.
This table summarizes RNU6-237P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-237P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-237P shows lower tumor expression in BRCA, THCA and LIHC and higher tumor expression in KIRC, CHOL and COAD. The BRCA box plot shows higher RNU6-237P RNA expression in normal versus tumor tissue (log2 FC = −0.206, t-test p = .018).
This table shows molecular features associated with RNU6-237P in patient tissues and cancer cell lines. In patient samples, RNU6-237P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
